<DOC>
	<DOC>NCT01985373</DOC>
	<brief_summary>Intravenous immunoglobulin (IVIG) is used for treatment of a heterogeneous group of immune related disorders both as immune-replacement and immune-modulating therapy. Sanquin developed a 100 mg/ml IVIg product (Nanogam 100 mg/ml). Patient will receive one infusion with Nanogam 50 mg/ml as they used to (same dose) and subsequently 4 infusions with Nanogam 100 mg/ml (same dose). Aim is to show bioequivalency between the 50 mg/ml and the 100 mg/ml product of Sanquin.</brief_summary>
	<brief_title>Pharmacokinetics and Safety of IVIG Nanogam 100 mg/ml</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Immunoglobulins, Intravenous</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Rho(D) Immune Globulin</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Primary a or hypogammaglobulinemia, particularly patients with XLA or CVID Stabilised on treatment with Nanogam 50 mg/ml with 24 weeks intervals in an hospital or at home and willing to be treated with 1 infusion of Nanogam 50 mg/ml and 4 infusions of Nanogam 100 mg/ml at the hospital A stable clinical situation (no activity of any other disease; a stable immunoglobulin dose and frequency) Age &gt;= 18 years The patient has signed the consent form Known with allergic reactions against human plasma or plasma products Having an ongoing progressive disease, including HIV infection Pregnancy or lactation Known with insufficiency of coronary or cerebral circulation Having renal insufficiency (plasma creatinin &gt; 115Âµmol/L) Having IgA deficiency and antiIgA antibodies have been detected</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>intravenous immunoglobulin</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>10% IVIG</keyword>
</DOC>